Therapeutic Indications for Prazosin
Prazosin is FDA-approved for the treatment of hypertension, and it is also widely used off-label for PTSD-associated nightmares and sleep disturbances, though recent evidence has downgraded this recommendation due to conflicting trial results. 1
FDA-Approved Indication
Hypertension
- Primary indication: Lowering blood pressure to reduce cardiovascular morbidity and mortality, particularly stroke and myocardial infarction 1
- Can be used as monotherapy or combined with other antihypertensives (diuretics, beta-blockers) 1
- Dosing: Start 1 mg at bedtime, titrate to 2-20 mg daily in 2-3 divided doses 2
- Important caveat: Alpha-1 blockers like prazosin are associated with orthostatic hypotension, especially in older adults, and are considered second-line agents for hypertension, potentially useful in patients with concomitant benign prostatic hyperplasia 2
Off-Label Use: PTSD-Associated Nightmares
Current Evidence Status
The evidence for prazosin in PTSD nightmares is contradictory and has been downgraded, though many clinicians observe individual patient responses:
Supporting evidence (older, smaller studies):
- Multiple RCTs from 2010-2013 showed significant reductions in nightmare frequency and PTSD symptoms in both military veterans and civilians 3
- A 2021 meta-analysis of 6 RCTs (429 patients) found statistically significant improvements in overall PTSD scores (SMD = -0.31), nightmares (SMD = -0.75), and sleep quality (SMD = -0.57) 4
Contradictory evidence (most recent, largest study):
- A 2018 VA study of 304 participants with chronic PTSD found no significant difference between prazosin (mean dose 14.8 mg) and placebo at 10 or 26 weeks on any outcome measure 3
- This led the American Academy of Sleep Medicine Task Force to unanimously downgrade their recommendation 3
Clinical Recommendation Despite Mixed Evidence
The 2018 AASM position paper states: "it is clearly apparent to clinicians that many patients respond very well to prazosin and this agent remains the first choice for pharmacologic therapy" for nightmare disorder 3
When to Consider Prazosin for PTSD Nightmares:
- Patient has failed or is unresponsive to first-line treatments (trauma-focused psychotherapy, antidepressants) 5
- Nightmares and insomnia are the dominant PTSD symptoms 5
- Exclude treatable conditions like obstructive sleep apnea first 5
- Use as adjunct to ongoing psychotherapy and antidepressants (91% of best responders were on antidepressants in one study) 6
Dosing for PTSD Nightmares:
- Start: 1 mg at bedtime 7
- Titrate: Increase by 1-2 mg every few days based on response 7
- Target doses:
- Critical caveat: Response may be reduced in patients taking SSRIs concurrently 3
Monitoring Requirements:
- First-dose hypotension: Monitor blood pressure after initial dose 1
- Orthostatic hypotension and syncope risk (approximately 1% with doses ≥2 mg initially) 1
- Blood pressure monitoring during titration 5
- Assess nightmare frequency and sleep quality 5
- Duration: Use for targeted, time-limited trial with adequate dose for adequate duration 5
Other Off-Label Uses (Limited Evidence)
Benign Prostatic Obstruction
- Improves maximum/average flow rates, reduces residual volume and obstructive symptoms 8
- Alpha-1 blockers are recognized for BPH treatment, though newer agents (terazosin, doxazosin) are more commonly used 2
Congestive Heart Failure
- Historical use showing balanced arterial and venous dilation comparable to nitroprusside 9
- Not a current standard treatment
Critical Safety Warnings
Syncope risk:
- Can cause sudden loss of consciousness, typically 30-90 minutes after initial dose 1
- Always start with 1 mg capsules; 2 mg and 5 mg capsules are NOT for initial therapy 1
- Risk minimized by slow titration and cautious addition of other antihypertensives 1
Priapism:
- Prolonged erections reported in post-marketing surveillance 1
- Seek immediate medical attention if erection persists >4 hours 1
Drug interactions:
- Hypotension may develop when combined with beta-blockers 1